Skip to content

Homoeopathy in LM Potency and Atopic Dermatitis(AD) in Paediatric age group.

ROLE OF INDIVIDUALIZED HOMOEOPATHIC MEDICINES USING 50 MILLESIMAL POTENCY IN REDUCING ABSOLUTE EOSINOPHIL COUNT (AEC) IN PAEDIATRIC ATOPIC DERMATITIS: A SINGLE ARM PRE- POST ASSESMENT INTERVENTIONAL STUDY - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099773
Enrollment
50
Registered
2025-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Individualized Homoeopathic medicine in LM potency: Administering indicated homoeopathic medicine for a period of 6 months, as decided appropriate to the case. Potency: Medicine will be

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient in the age group of 3 to 17 years. 2.All gender, regions and races irrespective of socioeconomic status. 3.Patients fulfilling Hanifin and Rajka diagnostic criteria for atopic dermatitis. 4.Absolute eosinophil count (AEC) more than 500 cells per mm 5.Patients already undergoing oral/topical conventional therapy for Atopic dermatitis may be recruited after a washout period of 1 month. 6.Parent or guardian willing to give written consent; assent from children (Below 7 years: no assent required,7 to 11 years Verbal assent ,more than 12 years written assent) 7.Parent orguardian (or child, if more than 7 years) ability to understand Bengali or Hindi or English.

Exclusion criteria

Exclusion criteria: 1.Complicated cases of atopic dermatitis. 2.Patients with congenital anomalies, critically ill patients, immune compromised patient. 3.Patient suffering from any other uncontrolled systemic diseases. 4.Diagnosed cases of unstable mental or psychiatric illness. 5.Patient having any substance abuse.

Design outcomes

Primary

MeasureTime frame
Absolute eosinophil count (AEC)Timepoint: Measured at baseline and after 6 months of treatment

Secondary

MeasureTime frame
SCORAD IndexTimepoint: Measured at baseline and after 6 months of treatment.;Modified Naranjo Criteria for Homeopathy (MONARCH)Timepoint: Measured at 6 months after treatment

Countries

India

Contacts

Public ContactDr Shishir Kumar Singh

National Institute of Homoeopathy

drshishirsinghmd@gmail.com8240898749

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026